DSIP

weak data

Also seen as: Delta Sleep-Inducing Peptide, delta sleep-inducing peptide

The Dose Guy’s verdict

Aug 29, 2026
4 sources

The name promises more than the data delivers. DSIP has been around since 1977, and in all that time nobody has proven it actually induces delta sleep in any reliable, repeatable way. The handful of small human trials from the 1980s and 1990s are mixed at best, and the basic biology, its gene, its receptor, its actual source in the body, remains unresolved. People run it, people report sleeping better on it, and no alarming safety signal has emerged from decades of scattered community use. But if you want a sleep compound with real evidence behind it, trazodone or lemborexant will do more for you.

Would I take it?Interesting, but unproven.

What it is

Delta sleep-inducing peptide, a nine-amino-acid chain first isolated from rabbit blood in 1977 during an experiment looking for sleep factors. The name stuck, but the science underneath it never firmed up. No gene for DSIP has been found, no receptor has been identified, and a 2006 review called the proposed link between DSIP and sleep extremely poorly documented. What does exist is a peptide that people inject or inhale, report gentler and deeper sleep from, and that has not produced any alarming safety signal in decades of scattered use.

It is the only actual peptide on the sleep shelf. Everything else here, from trazodone to lemborexant, is a small-molecule pharmaceutical filled at a pharmacy. DSIP comes from peptide vendors, with all the sourcing and purity questions that entails.

What the research shows

A handful of small, old human trials and a mechanism review that raises more questions than it answers:

In 16 chronic insomniacs, three intravenous doses produced higher sleep efficiency and shorter sleep latency than placebo, but the effects were weak and subjective sleep quality did not improve. The investigators called the therapeutic benefit unlikely.Neuropsychobiology 1992 · RCT · n=16

A four-night double-blind crossover found no significant improvement in awakenings, NREM latency, or waking time versus placebo or baseline. The investigators judged the improvement of little clinical significance.Eur Neurol 1987 · crossover · n=unclear

Seven nightly administrations brought sleep and daytime rest to normal-control levels, with benefits appearing after the first dose and persisting through the first post-treatment night.Eur Neurol 1987 · controlled · n=14

A comprehensive review found DSIP’s natural occurrence, biological activity, and link to sleep obscure. No gene, no receptor, no clear mechanism, 29 years after discovery.J Neurochem 2006 · review

Realistic protocols

The evidence is too thin for a confident protocol, so treat this as what people actually run, not what trials support. Most community protocols use 100 to 300 mcg subcutaneously or intranasally, 30 to 60 minutes before bed, for runs of a few weeks at a time. DSIP degrades fast in blood, so timing matters more than dose.

Some people run it nightly, some a few nights a week. There is no evidence that one schedule is better than another. Alcohol disrupts the sleep DSIP is aimed at, so using both the same night defeats the purpose. No evidence that DSIP builds tolerance or causes withdrawal. It is among the gentlest things on the sleep shelf in that regard.

If you try it, log your sleep honestly: the placebo response to a peptide with “delta sleep” in the name is enormous, and the only way to know whether it is doing anything is to track it.

Dose100–300 mcgSub-q or intranasal, 30–60 min before bed.

Run length2–4 weeksThen reassess. No evidence for continuous use over cycling.

Side effects

Nothing alarming has surfaced, but almost nothing has been systematically measured:

anecdotalVivid dreams, reported commonly and usually described as neutral or positive.

anecdotalMild drowsiness or grogginess if the dose runs high.

monitorIn 24 women under general anesthesia, intravenous DSIP raised heart rate, cut heart-rate variability, and reduced delta rhythm. A peptide named for delta sleep measurably reducing it is the kind of finding that deserves attention.

unknownNo long-term human safety data exists. DSIP’s own mechanism is unresolved, which means there is no map of what chronic use might do.